Clinical Trial Update: A Study to Evaluate the Safety and Ability of the Vaccine to Induce Antibodies Against the Respiratory Syncytial Virus in Healthy Adults [Phase 1]

View source ↗

Summary

A Phase 1 study assessing safety and antibody-inducing potential of an RSV vaccine in healthy adults; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• GSK RSV vaccine (investigational) (unknown)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus (RSV) | Phase 1 | Status: COMPLETED | Results posted: 2018-08-13